Evidence of nonlinearity in digoxin pharmacokinetics
- PMID: 7277206
- DOI: 10.1007/BF01068079
Evidence of nonlinearity in digoxin pharmacokinetics
Abstract
Six normal male volunteers received 0.5 mg label doses of digoxin as (a) a bolus intravenous injection over 2 min, (b) a constant rate intravenous infusion over 1 hr, (c) a constant rate intravenous infusion over 3 h, and (d) a solution in 5% dextrose given orally. Plasma concentrations of digoxin were measured by radioimmunoassay for a 4 day period and urinary excretion for a 6 day period after the single doses. The mean (coefficient of variation) total areas under the plasma concentration-time curves per 0.5 mg of digoxin were (a) 35.55 (14.8%), (b) 30.20 (27.7%), (c) 25.80 (35.5%), and (d) 15.47 (49.9%); the means differed significantly (0.01 greater than p greater than 0.005). The mean (coefficient of variation) total amounts excreted in the urine as a fraction of the dose were (a) 0.689 (6.31%), (b) 0.517 (20.4%), (c) 0.588 (16.8%), and (d) 0.374 (23.4%); the means differed significantly (p less than 0.001). Both the total clearance and the nonrenal clearance of digoxin differed significantly with the method of intravenous administration. The slower the rate of input of digoxin to the body, the greater were both the total clearance and the nonrenal clearance of the drug, which strongly suggests nonlinear pharmacokinetics.
Similar articles
-
Lack of difference in digoxin urinary excretion with two intravenous infusion rates.Clin Pharmacol Ther. 1981 Sep;30(3):317-20. doi: 10.1038/clpt.1981.166. Clin Pharmacol Ther. 1981. PMID: 7273595
-
Absolute bioavailability of digoxin tablets.Arzneimittelforschung. 1978;28(4):701-3. Arzneimittelforschung. 1978. PMID: 581950 Clinical Trial.
-
[Biological availability of digoxin and beta-acetyldigoxin after single-dose administration (author's transl)].Dtsch Med Wochenschr. 1979 Apr 13;104(15):543-6. doi: 10.1055/s-0028-1103942. Dtsch Med Wochenschr. 1979. PMID: 436626 Clinical Trial. German.
-
Clinical pharmacokinetics of amiodarone.Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002. Clin Pharmacokinet. 1984. PMID: 6370540 Review.
-
Clinical pharmacokinetics of digoxin.Clin Pharmacokinet. 1977 Jan-Feb;2(1):1-16. doi: 10.2165/00003088-197702010-00001. Clin Pharmacokinet. 1977. PMID: 322907 Review.
Cited by
-
Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.AAPS J. 2017 Jan;19(1):298-312. doi: 10.1208/s12248-016-0009-9. Epub 2016 Nov 7. AAPS J. 2017. PMID: 27822600
-
On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.Eur J Clin Pharmacol. 1983;25(3):369-73. doi: 10.1007/BF01037950. Eur J Clin Pharmacol. 1983. PMID: 6628525
-
On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations.J Pharmacokinet Biopharm. 1986 Aug;14(4):357-64. doi: 10.1007/BF01059196. J Pharmacokinet Biopharm. 1986. PMID: 3772737
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources